Fairmount Funds Management LLC - 09 Jun 2026 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Reporting relationship: Director
Issuer ticker: APGE
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 20:04:19 UTC
Prior SEC filing: 03 Jun 2026
Next SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 11 Jun 2026.

Key facts

This page summarizes Fairmount Funds Management LLC's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
1 reported transaction and 2 derivative rows are listed below.
Accepted by SEC: 11 Jun 2026, 20:04.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001802528 Primary reporting owner

Fairmount Funds Management LLC

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Signature date: 11 Jun 2026

CIK 0001830177

Kiselak Tomas

Relationship: Director
Address: 2001 MARKET STREET, SUITE 2500, PHILADELPHIA
Signature: /s/ Tomas Kiselak
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +7,657
Change %
Price: $0.000000^*
Shares after: 7,657
Date: 09 Jun 2026
Ownership: By: Tomas Kiselak
Underlying class: Common Stock
Underlying amount: 7,657
Exercise price: $85.00
Footnotes: F1, F2

APGE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +7,657
Change %
Price: $0.000000^*
Shares after: 7,657
Date: 09 Jun 2026
Ownership: By: Tomas Kiselak
Underlying class: Common Stock
Underlying amount: 7,657
Exercise price: $85.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

Footnote F2

Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC remarks

Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of Issuer and is a Managing Member of Fairmount.